Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: A randomized trial

Diabetic Medicine

Volumn 32, Issue 3, 2015, Pages 374-381

  Joergensen, C ^a   Tarnow, L ^a,c   Goetze, J P ^b,c   Rossing, P ^a,c,d  

^a STENO DIABETES CENTER   (Denmark)

^b University of Copenhagen   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; CALCIUM; COPEPTIN; EDETATE CHROMIUM CR 51; HEMOGLOBIN A1C; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PLACEBO; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; ERGOCALCIFEROL; GLYCOPEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); VITAMIN D;

ADULT; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PATELLA FRACTURE; PHOSPHATE BLOOD LEVEL; PLASMA CLEARANCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT COURSE THERAPY; TASTE DISORDER; URINARY EXCRETION; VITAMIN SUPPLEMENTATION; AGED; ALBUMINURIA; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG EFFECTS; INCIDENCE; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; URINE;

ADULT; AGED; ALBUMINURIA; BIOMARKERS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ERGOCALCIFEROLS; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; INCIDENCE; KIDNEY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS; VITAMIN D;

EID: 84922569437     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12606     Document Type: Article

References (28)

1. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B et al. Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-1349.
2. Young KA, Snell-Bergeon JK, Naik RG, Hokanson JE, Tarullo D, Gottlieb PA et al. Vitamin D deficiency and coronary artery calcification in subjects with type 1 diabetes. Diabetes Care 2011; 34: 454-458.
3. Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care 2011; 34: 1081-1085.
4. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving H-H, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care 2010; 33: 2238-2243.
5. Joergensen C, Reinhard H, Schmedes A, Hansen PR, Wiinberg N, Petersen CL et al. Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate. Diabetes Care 2012; 35: 168-172.
6. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr. et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
7. Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005; 48: 149-155.
8. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006; 49: 2256-2262.
9. Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 336-339.
10. de Boer I, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69-77.
11. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
12. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
13. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
14. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005; 48: 156-163.
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
16. Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35-45.
17. Theilade S, Joergensen C, Persson F, Lajer M, Rossing P. Ambulatory tonometric blood pressure measurements in patients with diabetes. Diabetes Technol Ther 2012; 14: 453-456.
18. Nair D, Tan SY, Gan HW, Lim SF, Tan J, Zhu M et al. The use of ambulatory tonometric radial arterial wave capture to measure ambulatory blood pressure: the validation of a novel wrist-bound device in adults. J Hum Hypertens 2008; 22: 220-222.
19. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26: 485-490.
20. Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R et al. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011; 33: 139-149.
21. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1, 25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696-1705.
22. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647-652.
23. Parving H-H, Mauer M, Ritz E. Diabetic Nephropathy. In: Brenner BM ed. Brenner & Rector's The Kidney, 8th ed. Boston, USA: WB Saunders, 2008: 1265-1298.
24. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
25. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105: 15896-15901.
26. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806.
27. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
28. Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD. Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int 2011; 80: 1073-1079.